Ursodeoxycholic Acid Therapy and the Risk of Colorectal Adenoma in Patients With Primary Biliary Cirrhosis: An Observational Study
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Ursodeoxycholic acid (UDCA) is the first–line treatment for primary biliary cirrhosis (PBC). The long–term administration of UDCA might indirectly favor colon carcinogenesis by increasing the fecal excretion of secondary bile acids or, in contrast, it might inhibit colon carcinogenesis, as demonstrated in animal models. In patients with PBC, we examined the effect of prolonged UDCA administration on the prevalence and recurrence of colorectal adenoma and on the proliferation of colon epithelial cells. One hundred fourteen patients (103 women, 11 men; mean age, 55 years) with PBC, were enrolled in a colonoscopic surveillance program. The prevalence of colon adenoma was compared in patients already treated with UDCA (mean duration 46 months) at the time of colonoscopy (treated group, n = 52) and in patients undergoing colonoscopy just prior to treatment initiation (untreated group, n = 62). The recurrence of adenoma following removal (mean follow–up, 35 months) was compared between UDCA–treated patients and appropriate age– and gender–matched controls (2/1) selected from a cohort of 205 patients undergoing polypectomy. Epithelial cell proliferation was assessed using anti–Ki67 antibodies on colon biopsies from both treated and untreated patients. Treated and untreated patients displayed similar demographic characteristics. The prevalence of colorectal adenomas was 13% in the treated group versus 24% in the untreated group (P = .16). The colon epithelial cell proliferation index was significantly lower in treated patients than in untreated patients (P = .001). Following removal of the adenoma, the probability of recurrence was significantly lower in patients treated with UDCA than in controls (7% vs. 28% at 3 years, P = .04). In conclusion, this study suggests that, in patients with PBC, the prolonged administration of UDCA (1) is not associated with an increased prevalence of colorectal adenomas, and (2) significantly decreases the probability of colorectal adenoma recurrence following removal. These results are strengthened by the significant reduction in colon epithelial cell proliferation seen in patients treated with UDCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Self-citationUnconjugated secondary bile acids in the serum of patients with colorectal adenomas.
Bayerdörffer, E., Mannes, G. A., Ochsenkühn, T., Dirschedl, P., Wiebecke, B., & Paumgartner, G. (1995) · Gut · doi:10.1136/gut.36.2.268 · Cited by 146 · cited 1×
“The surveillance program had three objectives: (1) to compare the prevalence of colorectal adenoma between patients at the outset of treatment and those already treated with UDCA, (2) to assess the risk of recurrence of adenoma in patients receiving UDCA compared with that observed in a gender- and age-matched control…”
Incidence of cancer in primary biliary cirrhosis: the Mayo experience
Nijhawan, P. K., Therneau, T. M., Dickson, R. E., Boynton, J., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510290511 · Cited by 99
Cited by
Bile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Diversification of host bile acids by members of the gut microbiota
Winston, J. A., & Theriot, C. M. (2020) · Gut Microbes · doi:10.1080/19490976.2019.1674124 · Cited by 587
Olsson, R., Boberg, K. M., Schaffalitsky de Muckadell, O., Lindgren, S., Hultcrantz, R., Folvik, G., Bell, H., Gangsøy–Kristiansen, M., Matre, J., Rydning, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.08.017 · Cited by 394
Bile acids: regulation of apoptosis by ursodeoxycholic acid
Amaral, J. D., Viana, R. J. S., Ramalho, R. M., Steer, C. J., & Rodrigues, C. M. P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900011-jlr200 · Cited by 363
The role of bile acids in carcinogenesis
Režen, T., Rozman, D., Kovács, T., Kovács, P., Sipos, A., Bai, P., & Mikó, E. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04278-2 · Cited by 298
Metadata
- Authors
- Serfaty, L., De Leusse, A., Rosmorduc, O., Desaint, B., Flejou, J.-F., Chazouilleres, O., Poupon, R. E., & Poupon, R.
- Venue
- Hepatology
- Published
- 2003-07
- Volume
- 38
- Issue
- 1
- Pages
- 203-209
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2016165032
- Cited by
- 117
- References
- 3
- FWCI
- 4.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ursodeoxycholic Acid Therapy and the Risk of Colorectal Adenoma in Patients With Primary Biliary Cirrhosis: An Observational Study. https://app.cochat.ai/papers/10.1053/jhep.2003.50311
- The paper
- Serfaty, L., De Leusse, A., Rosmorduc, O., Desaint, B., Flejou, J.-F., Chazouilleres, O., Poupon, R. E., & Poupon, R. (2003). Ursodeoxycholic Acid Therapy and the Risk of Colorectal Adenoma in Patients With Primary Biliary Cirrhosis: An Observational Study. Hepatology. https://doi.org/10.1053/jhep.2003.50311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.